X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
olaparib (152) 152
index medicus (139) 139
oncology (120) 120
ovarian cancer (113) 113
humans (107) 107
female (85) 85
poly polymerase (83) 83
mutation (78) 78
chemotherapy (74) 74
cancer (72) 72
olaparib maintenance therapy (66) 66
breast cancer (58) 58
ovarian neoplasms - drug therapy (57) 57
parp inhibitor (55) 55
tumors (52) 52
homologous recombination (49) 49
dna repair (48) 48
cancer therapies (45) 45
deoxyribonucleic acid--dna (45) 45
open-label (44) 44
poly polymerase inhibitors - therapeutic use (40) 40
parp inhibitors (39) 39
pharmacology & pharmacy (38) 38
dna damage (35) 35
ovarian neoplasms - genetics (35) 35
clinical trials (34) 34
research (33) 33
antineoplastic agents - therapeutic use (31) 31
synthetic lethality (31) 31
maintenance therapy (30) 30
brca (29) 29
brca1 protein - genetics (29) 29
double-blind (29) 29
repair (29) 29
care and treatment (27) 27
endocrine system diseases (27) 27
ovarian-cancer (27) 27
patients (27) 27
brca2 protein - genetics (26) 26
genetic aspects (26) 26
review (26) 26
brca1 (25) 25
drug therapy (25) 25
middle aged (25) 25
ovarian neoplasms - pathology (25) 25
poly polymerase inhibitors - pharmacology (24) 24
apoptosis (23) 23
breast-cancer (23) 23
multicenter (23) 23
phthalazines - therapeutic use (23) 23
ribose (23) 23
adult (22) 22
cell line, tumor (22) 22
fallopian-tube (22) 22
phase-i (22) 22
piperazines - therapeutic use (22) 22
aged (21) 21
combination (21) 21
metastasis (21) 21
parp (21) 21
therapy (21) 21
antineoplastic agents - pharmacology (20) 20
health aspects (20) 20
inhibitors (20) 20
neoplasms. tumors. oncology. including cancer and carcinogens (20) 20
phthalazines - administration & dosage (20) 20
piperazines - administration & dosage (20) 20
animals (19) 19
brca1 protein (19) 19
carcinoma (19) 19
monosaccharides (19) 19
mutations (19) 19
phthalazines - pharmacology (19) 19
sugars (19) 19
antineoplastic combined chemotherapy protocols - therapeutic use (18) 18
cell cycle (18) 18
dna-repair (18) 18
molecular targeted therapy (18) 18
piperazines - pharmacology (18) 18
polymerase (18) 18
analysis (17) 17
epithelial ovarian (17) 17
female genital diseases and pregnancy complications (17) 17
poly (17) 17
rucaparib (17) 17
carboplatin (16) 16
male (16) 16
negative breast-cancer (16) 16
ovarian carcinoma (16) 16
pegylated liposomal doxorubicin (16) 16
poly polymerase inhibitors (16) 16
solid tumors (16) 16
somatic mutations (16) 16
bevacizumab (15) 15
brca mutation (15) 15
dna-damage (15) 15
fda approval (15) 15
poly polymerase inhibitors - administration & dosage (15) 15
proteins (15) 15
recurrent epithelial ovarian (15) 15
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gynecologic Oncology, ISSN 0090-8258, 2016, Volume 140, Issue 2, pp. 199 - 203
Journal Article
Trials [E], ISSN 1745-6215, 06/2016, Volume 17, Issue 1, pp. 293 - 293
Background: Preclinical studies in breast cancer models showed that BRCA1 or BRCA2 deficient cell lines, when compared to BRCA proficient cell lines, are... 
Capecitabine | PARP inhibitors | Carboplatin | Breast cancer | Metastatic | Olaparib | BRCA1 | BRCA2 | Homologous recombination deficiency | MEDICINE, RESEARCH & EXPERIMENTAL | 1ST-LINE TREATMENT | MECHANISM | POLYMERASE | COMBINATION | TUMORS | PACLITAXEL | OVARIAN | HOMOLOGOUS RECOMBINATION | DNA-REPAIR | Capecitabine - administration & dosage | Piperazines - administration & dosage | Compassionate Use Trials | Phthalazines - pharmacokinetics | Humans | Clinical Protocols | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carboplatin - pharmacokinetics | Carboplatin - adverse effects | Breast Neoplasms - enzymology | Drug Dosage Calculations | Netherlands | Time Factors | Female | Piperazines - pharmacokinetics | Genetic Predisposition to Disease | Phthalazines - administration & dosage | Biomarkers, Tumor - analysis | Carboplatin - administration & dosage | Treatment Outcome | Breast Neoplasms - drug therapy | Piperazines - adverse effects | Disease Progression | BRCA1 Protein - genetics | Disease-Free Survival | Phenotype | Breast Neoplasms - genetics | Capecitabine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Biomarkers, Tumor - genetics | Mutation | Receptor, ErbB-2 - analysis | Research Design | BRCA2 Protein - genetics | Phthalazines - adverse effects | Complications and side effects | Dosage and administration | Research | Drug therapy | Index Medicus
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 8/2014, Volume 74, Issue 2, pp. 257 - 265
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 02/2018, Volume 12, pp. 347 - 348
Iulian Alecu, Tsveta Milenkova, Simon R Turner Research and Development, AstraZeneca UK Limited, Cambridge, UKThe tolerability profile of PARP inhibitors often... 
OLAPARIB | PHARMACOLOGY & PHARMACY | CHEMISTRY, MEDICINAL | MUTATION | Complications and side effects | Cancer patients | Enzyme inhibitors | Drug therapy | Blood diseases | Risk factors | Clinical trials | Poly(ADP-ribose) polymerase | Toxicity | Health risks | Cancer | neutropenia | hematologic toxicities | PARP inhibitors | olaparib
Journal Article
Expert review of anticancer therapy, ISSN 1473-7140, 04/2019, Volume 19, Issue 6, pp. 437 - 446
The landscape of PARP inhibition in ovarian cancer is rapidly evolving and becoming increasingly complex. Ovarian cancer is leading therapeutic innovation - by... 
Rucaparib | ovarian cancer | SAFETY | PARP inhibitor | synthetic lethality | MECHANISMS | OLAPARIB MONOTHERAPY | MAINTENANCE THERAPY | ONCOLOGY | DOUBLE-BLIND | RESISTANCE | HOMOLOGOUS RECOMBINATION | CARCINOMA | EXPRESSION | GERMLINE BRCA1/2 MUTATION
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 11/2017, Volume 147, Issue 2, pp. 267 - 275
Journal Article
The Oncologist, ISSN 1083-7159, 06/2018, Volume 23, Issue 6, pp. 697 - 703
This review describes the adaptive analysis to determine the optimal olaparib tablet dose for patient and highlights the clinical considerations in... 
BRCA | mutation | Poly(ADP‐ribose) polymerase inhibitor | Olaparib, tablet | Ovarian cancer | BRCA mutation | Poly(ADP-ribose) polymerase inhibitor | MEDICATION | MONOTHERAPY | Olaparib | PARP | MAINTENANCE THERAPY | ADHERENCE | tablet | ONCOLOGY | DOUBLE-BLIND | QUALITY-OF-LIFE | PILL BURDEN | TREATMENT SATISFACTION | GERMLINE BRCA1/2 MUTATION | Gynecologic Oncology
Journal Article
Journal Article